All News
Filter News
Found 808,979 articles
-
Viridian Therapeutics Reports 2020 Financial Results and Provides Corporate Updates
3/25/2021
Progressed lead programs VRDN-001 and VRDN-002 towards clinical trials in Thyroid Eye Disease (TED); both IND filings expected by the end of 2021 Completed integration and name change to Viridian Therapeutics following October 2020 merger and concurrent financing
-
Athira Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Highlights
3/25/2021
– LIFT-AD and ACT-AD studies evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer’s disease, actively enrolling patients – – IND submissions planned for Parkinson’s disease dementia program in 1H 2021 and neuropsychiatric program by end of 2021 –
-
Neoleukin Therapeutics Announces Year End 2020 Financial Results
3/25/2021
- Anticipating first patient for NL-201 Phase 1 Trial in 1H21 - - Cash and cash equivalents of $192.6 million expected to fund operations into 2023 - - Company to host Conference Call Today, March 25, 2021 at 1:30 p.m. Pacific / 4:30 p.m. Eastern -
-
Chemence Opens New Research and Development Facility
3/25/2021
Chemence, a global company with specialized expertise in the field of polymerizable technology, announced the opening of the Chemence Center of Excellence, a state-of-the-art research and development facility in Alpharetta, Georgia.
-
Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates
3/25/2021
Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021 Cash Position Expected to Fund Operations into the Second Quarter of 2022
-
Triple-S Management Corporation Announces Appointment of Victor J. Haddock as Chief Financial Officer
3/25/2021
Triple-S Management Corporation (NYSE: GTS), a leading health services company in Puerto Rico, today announced that it has appointed Victor J. Haddock-Morales as Executive Vice President and Chief Financial Officer, effective May 10, 2021
-
OpenEye Scientific Achieves AWS High Performance Computing Competency
3/25/2021
OpenEye Scientific, developer of the world’s only cloud-native molecular design platform, Orion,™ announced today that it is among the first of only a handful of companies globally that have achieved Amazon Web Services (AWS) High Performance Computing (HPC) Competency status.
-
Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results
3/25/2021
Announces MydCombi expected PDUFA date of October 28, 2021 Completes patient enrollment in Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia; topline data on track for Q2 Company to host conference call and webcast today, March 25, at 4:30 pm ET NEW YORK, March 25, 2021
-
Movano Inc. Appoints Medtech Industry Veteran John Mastrototaro, PhD, as CEO
3/25/2021
Today, Movano Inc. (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health in order to prevent and better manage chronic diseases, announced current Director, Dr. John Mastrototaro, will join the Company as CEO, effective April 1, 2021
-
Kane Biotech Announces Fourth Quarter and Full Year 2020 Financial Results
3/25/2021
Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced its fourth quarter and full year 2020 financial results.
-
Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain
3/25/2021
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab.
-
Athersys Announces Financial Results for Fourth Quarter and Full Year 2020
3/25/2021
Athersys, Inc. (NASDAQ: ATHX) announced today its fourth quarter 2020 and annual 2020 financial results and recent highlights.
-
Upland CA ProMedify FirstAid CPR Certification Healthcare ContinuingEducation
3/25/2021
Newly updated CPR and first aid training courses have been launched by ProMedify. They work with both health professionals and non-healthcare workers to provide valuable training that can be immediately applied in real-life situations.
-
European Medicines Agency Validates Marketing Authorization Application for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer
3/25/2021
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for sacituzumab govitecan-hziy (SG) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies, including at least one prior therapy for locally advanced or metastatic disease
-
Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated PneumoniaTopline data expected in the first half of 2021
3/25/2021
Angion Biomedica Corp. announced completion of enrollment for its ALI-201 study, a Phase 2 trial conducted in Brazil of ANG-3777 for the reduction of severity and progression of acute lung injury in patients with COVID-19 associated pneumonia who are at high risk of progressing to acute respiratory distress syndrome, or ARDS.
-
4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights
3/25/2021
- First patient dosed in the 4D-310 Phase 1/2 clinical trial in Fabry disease - Intravitreal product candidates, 4D-125 for the treatment of XLRP and 4D-110 for the treatment of choroideremia, completed dose escalation portion of Phase 1/2 clinical trials (n=12 patients) - Intravitreal product candidate 4D-150 for the treatment of wet AMD and DME on track to initiate clinical trial in the second half of 2021
-
Certara Announces Pricing of Public Offering of Common Stock - Mar 25, 2021
3/25/2021
Certara, Inc., a global leader in biosimulation, announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders at a price to the public of $25.00 per share.
-
Takeda Begins Regulatory Submissions for Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
3/25/2021
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency (EMA) has accepted the Company’s filing packages for its dengue vaccine candidate (TAK-003) which is being investigated for the prevention of dengue due to any dengue virus serotype in individuals ages four to 60
-
Co-Diagnostics Reports Fourth-Quarter and Full-Year 2020 Financial Results
3/25/2021
Record quarterly results highlighted by revenue of $27.1 million and pre-tax income of $15.8 million
-
Varian Medical Systems Invests in Bend It Technologies, Ltd., a Company Developing Novel Steerable Microcatheters
3/25/2021
Varian (NYSE: VAR) today announced a new investment in Bend It Technologies Ltd., a medical device company based in Petach Tikva, Israel, that is developing the Bendit® steerable microcatheters for use by interventionalists performing minimally-invasive peripheral vascular procedures.